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ABSTRACT
Treatment of medulloblastoma in children fails in approximately 30% of patients, 
and is often accompanied by severe late sequelae. Therefore, more effective drugs 
are needed that spare normal tissue and diminish long-term side effects. Since 
radiotherapy plays a pivotal role in the treatment of medulloblastoma, we set out to 
identify novel drugs that could potentiate the effect of ionizing radiation.
Thereto, a small molecule library, consisting of 960 chemical compounds, 
was screened for its ability to sensitize towards irradiation. This small molecule 
screen identified the flavonoid quercetin as a novel radiosensitizer for the 
medulloblastoma cell lines DAOY, D283-med, and, to a lesser extent, D458-med 
at low micromolar concentrations and irradiation doses used in fractionated 
radiation schemes. Quercetin did not affect the proliferation of neural precursor 
cells or normal human fibroblasts. Importantly, in vivo experiments confirmed the 
radiosensitizing properties of quercetin. Administration of this flavonoid at the 
time of irradiation significantly prolonged survival in orthotopically xenografted 
mice. Together, these findings indicate that quercetin is a potent radiosensitizer 
for medulloblastoma cells that may be a promising lead for the treatment of 
medulloblastoma in patients.
INTRODUCTION
Medulloblastoma, the most common malignant brain 
tumor in children, accounts for approximately 20% of all 
intracranial childhood tumors [1]. Currently, patients are 
stratified into different risk groups based on histological 
features, clinical criteria, biological profile, and age. In 
general, treatment consists of surgery and craniospinal 
radiotherapy, followed by an additional irradiation 
boost aimed at the primary tumor site (clinicaltrials.gov 
NCT02066220). Children <3-5 years (age depending on the 
country) are treated with chemotherapy only [2, 3]. Although 
such treatment has resulted in remarkable improvement in 
outcome, this therapy still fails in approximately 30% of 
medulloblastoma patients [4]. Moreover, such therapy 
causes severe long-term side effects that significantly 
impact quality of life, especially in younger children [5–11]. 
Thus, there is a need for alternative therapies that allow to 
lower the total dose of irradiation or increase the radiation 
efficacy. Besides new radiotherapy techniques that limit the 
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radiation doses to surrounding healthy tissues [12–14], new 
chemotherapeutics that specifically sensitize the tumor to 
irradiation may provide alternative therapies [15, 16].
Here, we screened a commercially available 
small molecule library consisting of 960 compounds 
(ActiTarg-K960) to identify radiosensitizers for 
human medulloblastoma cells. and identified quercetin 
(3,3’,4’5,7-pentahydroxyflavone), a flavonoid found in 
fruits, vegetables and grains, as a potent radiosensitizer. 
Quercetin treatment at low micromolar concentrations did 
not affect cell proliferation when used as monotherapy, while 
the combination with irradiation significantly decreased 
medulloblastoma cell growth. Importantly, this sensitizing 
effect was not found on neural precursor cells, or normal 
human fibroblasts. In addition, quercetin treatment enhanced 
the in vitro sensitivity to radiation of medulloblastoma 
cell lines in clonogenic survival assays. However, the 
radiosensitizing effect was not observed in two primary 
medulloblastoma cell cultures. Finally, we observed that 
quercetin administration to orthotopically xenograft mice 
around the time of irradiation significantly prolonged 
survival. A flow chart, illustrating the experimental design, 
is available as Supplementary Figure S1. Since quercetin 
sensitizes medulloblastoma cells in our experiments at 
radiation doses used in fractionated radiation schemes, 
and the quercetin concentrations used can easily be 
achieved by oral administration, we suggest that the use 
of quercetin should be further evaluated in clinical trials in 
medulloblastoma patients in the near future.
RESULTS
Identification of quercetin as a radiosensitizer 
for medulloblastoma
In order to enable the identification of novel 
radiosensitizers for medulloblastoma, a small molecule 
screen was performed using DAOY medulloblastoma cells 
that were transduced with a lentiviral Gaussia luciferase 
(Gluc) vector co-expressing the fluorescent ‘Cerulean’ (CFP) 
reporter [17]. Expression of these genes allowed to monitor 
cell survival by bioluminescent and fluorescent read-out of 
cell viability. To optimize screening conditions, the well-to-
well and plate-to-plate variation, number of DAOY cells, 
and the dose of irradiation were determined. When assayed 
for Gluc luciferase activity, a variation coefficient (CV) of < 
7% was observed in four independent experiments (Figure 
1A), indicating only minimal variation in pipetting errors, 
substrate stability and measurement errors. An even better 
CV of < 2% was observed (Figure 1A) when measured by 
Acumen technology, where equal numbers of cells were 
plated and detected by CFP expression. Since both assays 
allowed to monitor cell viability at different time points after 
treatment, we optimized our screening conditions – number 
of cells, dose of irradiation, and drug concentrations – by 
measuring Gluc secretion or cell numbers in time (Figure 
1B-1D). This resulted in a four-day assay, using 750 DAOY 
cells per well with 4 Gy irradiation. In addition, a drug 
concentration of 1 μM was chosen, since this showed good 
results in a pilot experiment using eight different, randomly 
chosen small molecules (Figure 1D), and yielded positive 
hits in a drug screen performed previously by our group 
[18]. To identify putative radiosensitizers, cells were treated 
with compounds from the ActiTarg-K960 drug library 
consisting of 960 putative kinase inhibitors, or with 0.1% 
DMSO as an internal control, either as monotherapy, or in 
combination with irradiation. A reduction of >75% of cell 
growth after four days of incubation as compared to the 
DMSO controls was considered to be significant (Figure 
2A). In four separate screens, a total of 23 compounds was 
identified that consistently inhibited cell growth or sensitized 
towards irradiation, with 12 compounds inducing cell death 
independently of irradiation, and 11 compounds functioning 
as radiosensitizers (Table 1 and Supplementary Figure S2). 
Cytotoxicity of these 23 compounds was subsequently 
determined on primary human fibroblasts and on C17.2 
neuronal precursor cells (NPCs), to assess the therapeutic 
window (Table 1). This smaller screen narrowed our list of 
putative novel compounds for use in medulloblastoma down 
to five: two radiosensitizing agents and three compounds 
that have been identified as inducers of cell death in 
DAOY cells independently of irradiation (Figure 2B). 
The flavonoid quercetin was among these radiosensitizing 
compounds. Treatment with quercetin 30 minutes prior 
to irradiation resulted in a 5-fold reduction in cell growth 
(~20% cell survival), while treatment with quercetin alone 
did not significantly affect cell viability compared to cells 
treated with the solvent DMSO (Figure 2C). Irradiation 
without addition of quercetin resulted in a 2-fold reduction 
in cell numbers. As mentioned above, these results were not 
observed in primary human fibroblasts or neuronal precursor 
cells (Figure 2C).
Quercetin sensitizes medulloblastoma cells to 
radiation in vitro
Since quercetin has been reported to effectively cross 
the blood-brain-barrier [19], we hypothesized that this 
compound could be an attractive agent for the treatment 
of medulloblastoma. Therefore, we investigated if similar 
effects could be observed in additional medulloblastoma 
cell lines. D283-med, D458-med, and DAOY cells were 
incubated with 1 μM quercetin 30 minutes prior to irradiation, 
and cell numbers were determined at 4 days after treatment 
(Figure 3A). A radiosensitizing effect of quercetin was 
observed in DAOY and D283-med cell lines, while quercetin 
treatment by itself did not inhibit cell proliferation in any of 
the tested cell lines. To further confirm the radiosensitizing 
potential of quercetin, dose-dependent clonogenic survival 
assays were performed. Although DAOY cells are reported 
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Figure 1: Determination of screening conditions. A. Reproducibility of Gluc measurements (upper panel) or cell counts as measured 
by Acumen technology (lower panel). Aliquots of Gluc-containing medium or equal numbers of cells were plated in 96-well plates in 
quadruplicate, and measured to assess plate-to-plate and well-to-well variation (RLU=relative luciferase units). Data are presented as means 
± SD. The corresponding coefficients of variation (CV) are depicted in the right-hand panels. B. Growth curves of DAOY medulloblastoma 
cells. One hundred, 250, 500, 750, or 1000 cells were plated per well and set at 100%. Relative cell numbers were measured at different 
time points after plating as indicated in the figure. A plating density of 750 cells/well resulted in exponentially growing cells after 4 days 
of incubation that could be monitored without much variation. Data are presented as means ± SD (n=3). C. Graphic representation of the 
irradiation response in DAOY cells. Growth of non-irradiated (NI) cells is set at 100%. For each irradiation dose 8 samples were measured. 
D. concentration curves of DAOY medulloblastoma cells treated for four days with 0, 0.5, 1, or 2 μM of different drugs. Compounds 
were chosen randomly from the TimTec library: ST027883 (-■-), ST004727 (-●-), ST053862 (-▲-), ST012157 (-▼-), ST012256 (-♦-), 
ST029265 (-○-), ST036501 (-□-), ST052055 (-Δ-). A drug concentration of 1 μM was (red dotted line) was used for the final screen.
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Figure 2: A small molecule screen identifies quercetin as a radiosensitizer in medulloblastoma cells. A. Example of a 
scatter plot of Gluc values (left panels) and Acumen read-out (right panels), representing cell survival after treatment of DAOY cells with 
1 μM of the ActiTarg-K960 small molecule library in the presence, or absence of irradiation (4 Gy). The fluorescence in the single wells as 
measured by the Acumen is represented as relative intensities of the color green, where black corresponds with little cells and green with 
many cells. When using Gluc as a read-out, cell viability was measured by luciferase activity and corrected for the toxicity of the solvent, 
0.1% DMSO (set to 100%). A reduction of >75% of cell growth was considered to be significant, as indicated by a dashed line. Each dot 
represents a single well; in position F05 a cytotoxic agent is identified, in position C09 a radiosensitizer. A representative 96-well plate 
is shown. B. Structure formulae of compounds that induce cell death in DAOY medulloblastoma cells but show limited cytotoxicity on 
primary human fibroblasts and on C17.2 neuronal precursor cells (NPCs). Two radiosensitizing agents and three compounds that induce cell 
death independently of irradiation have been identified. C. Graphic representation of relative cell survival in DAOY medulloblastoma cells 
(left panel), primary human fibroblasts (PHF, middle panel), or neural precursor cells (NPC, right panel) after quercetin (QC) treatment and/
or irradiation (IR), as extracted from the small molecule screen. Data are presented as means ± SD (n=3). ** p<0.005, Mann-Whitney U test.
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Table 1: Overview of compounds that induce cell death in DAOY medulloblastoma cells, as identified by a small 
molecule screen 
IUPAC name structure formula
Molecular 
weight (Da)
common name Fibroblasts
Neural 
Precursor 
Cells
(4-methoxyphenyl)
(2-methylbenzo[h]quinolin-4-yl)
amine, chloride
C21H19ClN2O 350,85 OK OK
6-amino-4-(9-ethylcarbazol-3-
yl)-3-methyl-4H-pyrano[3,2-d]
pyrazole-5-carbonitrile
C22H19N5O 369,43 OK OK
3-amino-1-(4-fluorophenyl)-1H-
benzo[f]chromene-2-carbonitrile
C20H13FN2O 316,33 OK OK
5-bromo-4-(4-cyclohexyl-5-
phenyl(1,2,4-triazol-3-ylthio))-
2-phenyl-2-hydropyri dazin-3-
one
C24H22BrN5OS 508,44 OK +/−
4,5-dichloro-2-[(4-fluorophenyl)
methyl]-2-hydropyridazin-3-one
C11H7Cl2FN2O 273,09 +/− +/−
3-[((1E)-2-(2-pyridyl)-1-
azavinyl)amino]-6-methyl-4H-
1,2,4-triazin-5-one
C10H10N6O 230,23 +/− cell death
3-[((1E)-2-(2-pyridyl)-1-
azavinyl)amino]-4H-1,2,4-
triazin-5-one
C9H8N6O 216,2 +/− cell death
1-cyclohexylazoline-2,5-dione C10H13NO2 179,22 N-cyclohexylmalemide cell death cell death
4,7-dimethylpyridino[3,2-h]
quinoline, oxamethane C14H14N2O 226,28 neocuproine cell death cell death
2,9-dimethylpyridino[3,2-h]
quinoline C14H12N2 208,26 neocuproine cell death cell death
5-((2E)-5,5-dichloropenta-2,4-
dienoyl)-6-methylpyran-2-one C11H8Cl2O3 259,09 cell death cell death
(8-chloro(4H-benzo[e]1,3-
thiazolo[5,4-c]thiin-2-yl))
naphthylamine
C20H13ClN2S2 380,92 cell death cell death
2-(3,4-dihydroxyphenyl)-3,5,7-
trihydroxychromen-4-one C15H10O7 302,24 quercetin OK OK
3-[(tert-butyl)amino]-1-(5-
methyl-2,3-diphenylindolyl)
propan-2-ol
C28H32N2O 412,57 OK OK
5-(4,6-dimethylpyrimidin-2-
ylthio)-4-nitrobenzo[c]1,2,5-
thiadiazole
C12H9N5O2S2 319,37 +/− OK
3-(indol-3-ylmethylene)
benzo[b]pyran-2,4-dione
C18H11NO3 289,29 +/− cell death
(Continued )
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to be clonogenic [20, 21], in our hands DAOY cells appeared 
unfit for these clonogenic experiments, since they did not 
form clones. However, treatment of D283-med and D458-
med medulloblastoma cells with 0.5 μM or 1 μM quercetin 
showed radiosensitization in both cell lines (Figure 3B), 
even at radiobiologically relevant irradiation doses of 1 
Gy or 2 Gy used in fractionated radiation schemes. These 
results strengthen our hypothesis that quercetin is a putative 
radiosensitizer for medulloblastoma. Next, we tested 
the radiosensitizing effect of quercetin on two primary 
medulloblastoma cell cultures, VU371 and ICb-1299MB 
[22]. Similar as for the cell lines, cells were treated with 1 
μM quercetin 30 minutes prior to irradiation, and viability 
was determined four days after treatment (Figure 3C). 
Again, quercetin by itself did not reduce cell viability, 
however, these cells are highly sensitive to radiation (data 
not shown). Therefore, cells were irradiated with the lowest 
technical dose possible, 0.7 Gy, which already significantly 
impaired viability. We did not observe an enhanced 
radiation response in combination with quercetin in these 
cells. Since medulloblastomas have been subclassified 
into four molecular subgroups [23], we determined to 
which subgroups the used cell lines belong. Expression 
of four subgroup classifier genes was assessed by qRT-
PCR, which was previously described by Zhao et al. [22] 
(Supplementary Figure S3A+B). DAOY was identified as a 
SHH-group like medulloblastoma while D283-med, D458-
med, and VU371 belonged to the group 3 subtype (Figure 
3D and Supplementary Figure S3A+B). ICb-1299MB was 
previously classified as a group 4 medulloblastoma [22].
Quercetin treatment improves radiation efficacy 
in a xenograft tumor model
To further evaluate if quercetin can function as a novel 
agent in the treatment of medulloblastoma, we investigated 
the effect of this compound in an in vivo setting, using an 
orthotopic xenograft mouse model. Therefore, luciferase-
expressing D283-med cells were implanted stereotactically 
into the left cerebellar hemisphere of nude mice. In two 
independent experiments, 31 out of 36 mice developed 
primary tumors, as judged by bioluminescent imaging 
(BLI) three weeks after implantation. These mice were 
then randomly assigned into four groups, and treated 
with vehicle (5% DMSO) or quercetin, either alone or in 
combination with irradiation. Since quercetin has a half-life 
of only 20 minutes in vivo [24], six consecutive injections 
with quercetin (100 mg/kg) were given at time points 
around the time of irradiation (60, 30 and 5 minutes before 
irradiation plus 30 and 60 minutes after irradiation and 24 
hours after irradiation). Quercetin treatment did not induce 
any neurological symptoms or other adverse events. Tumor 
growth was monitored twice a week by BLI. In addition, the 
mice were monitored daily for discomfort and weight loss. 
Although the BLI signal of the tumors did not differ between 
the various groups, survival analysis indicated a significant 
extension of the group that received ionizing radiation in 
combination with quercetin as compared to the vehicle-
treated group (p=0.0052), the quercetin group (p<0.0001), 
or the group that only received radiotherapy (p=0.002; 
Figure 4A). All animals treated with the combination of 
IUPAC name structure formula
Molecular 
weight (Da)
common name Fibroblasts
Neural 
Precursor 
Cells
5-[(1E)-2-(4-bromo-3-
chlorophenyl)-2-azavinyl]-2-
nitrothiophene
C11H6BrClN2O2S 345,6 +/− cell death
5-[(1E)-2-(2,4-dichlorophenyl)-
2-azavinyl]-2-nitrothiophene
C11H6Cl2N2O2S 301,15 +/− cell death
5-[(1E)-2-(4-iodophenyl)-2-
azavinyl]-2-nitrothiophene
C11H7IN2O2S 358,16 cell death cell death
6-(tert-butyl)-2-[3-(tert-butyl)-5-
bromo-2-hydroxyphenylthio]-4-
bromophenol
C20H24Br2O2S 488,28 cell death cell death
[(5-nitro-2-thienyl)methylene]
methane-1,1-dicarbonitrile C8H3N3O2S 205,2 cell death cell death
9-((1E)-2-nitrovinyl)anthracene C16H11NO2 249,27 cell death cell death
di2,3,4,5,6-pentafluorophenyl 
ketone
C13F10O 362,13 cell death cell death
Chemical compounds that repetitively induced cell death (upper panel) or functioned as radiosensitizers (lower panel) are 
represented. NPC=neural precursor cells; OK= no cell death as compared to control, +/− = ≤ 50% cell death.
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quercetin and irradiation survived for more than 24 days 
after treatment, with a median survival time of 32 days. 
Animals that did not receive irradiation (either vehicle- or 
quercetin-treated) had a median survival of only 12-17 days 
(Figure 4B).
DISCUSSION
Medulloblastoma therapy still fails in approximately 
30% of patients and is often accompanied by severe 
long-term sequelae. Thus, there still is a need for 
alternative therapies that allow to lower the total dose 
of irradiation, reducing the long-term side effects, and/
or increase the radiation efficacy. We show here that the 
flavonoid quercetin can sensitize medulloblastoma cells 
to irradiation, and that administration of quercetin during 
radiotherapy significantly improves survival in mice 
harboring medulloblastoma.
Quercetin was identified as a ‘ready-to-
use’ radiosensitizer in a small molecule screen for 
medulloblastoma cells, using two independent read-out 
systems. In this screen 23 compounds were repeatedly 
identified that could inhibit cell growth (n=12), or sensitize 
towards irradiation (n=11). Strikingly, two of the compounds 
that induced cell death independently of irradiation had 
similar structures, as did three of the 11 compounds that 
functioned as a radiosensitizer (nitrophenes, Supplementary 
Figure S2). However, most of those drugs also induced cell 
death in primary human fibroblasts or neuronal progenitor 
cells, rendering them unfit for the development of novel and 
tumor-specific therapies. Unlike those compounds, quercetin 
did not affect the proliferation of neuronal precursor cells or 
normal human fibroblasts, nor showed any toxicity in the 
absence of ionizing radiation. This is in concordance with 
previous studies that report selective activity of quercetin as 
a sensitizer to chemotherapeutics on cancer cells, but not in 
normal cells, even though higher quercetin concentrations 
(ranging from 5-200 μM) were used in these studies 
[25–27]. Moreover, quercetin has been shown to enhance 
radiation-induced cell death in rat hepatoma cells [28, 29]. 
Importantly, the low micromolar concentrations used in our 
experiments are in the range of the plasma concentrations 
Figure 3: Quercetin sensitizes towards irradiation in a panel of medulloblastoma cells. A. Graphic representation of relative 
cell survival of DAOY, D283-med, and D458-med cells after 4 days of quercetin treatment in the presence or absence of irradiation (4 Gy). 
Cell numbers were determined by visual counts, using a Bürker hemacytometer. Vehicle treated cells are set at 100%. Data are presented 
as means ± SD (n=3). ** p<0.005, Mann-Whitney U test. B. Clonogenic survival of D283-med (left panel) and D458-med (right panel) 
medulloblastoma cells, 14 days after irradiation (0-3Gy). Cells were treated with 0 μM (-●-), 0,5 μM (-○-), or 1 μM (-▼-) quercetin 30 
minutes prior to irradiation. A representative experiment is shown. C. Graphic representation of relative cell survival of VU371 and ICb-
1299MB cells after 4 days of quercetin treatment in the presence or absence of irradiation (0.7 Gy). Cell viability was determined by Cell 
Titer Glo assay. Vehicle treated cells are set at 100%. Data are presented as means ± SD. D. Molecular subgroup classification of DAOY, 
D283-med, D458-med, VU371, and ICb-1299MB cells. Expression levels of subgroup classifiers WIF1, SFRP1, NPR3, and KCNA were 
determined by qRT-PCR to determine to which subgroups the used medulloblastoma cells belong.
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that can be reached in humans and are considered to be safe 
[30, 31]. Quercetin is found in a broad range of fruits and 
vegetables such as apples, onions and tomatoes, and present 
in plasma at the nanomolar range (<100 nM) through our 
dietary intake, but micromolar concentrations have been 
reported after supplementation [32, 33].
The observation that the concentrations needed 
for therapeutic benefit can be easily achieved by 
oral administration, and the fact that quercetin is 
cheap and readily available, renders this flavonoid an 
interesting option for the treatment of children with 
medulloblastoma. Another motivation to consider 
quercetin as a radiosensitizer for this type of brain tumors, 
is the previously reported observation that quercetin can 
pass the blood-brain barrier (BBB) [34, 35]. The BBB 
is a natural boundary between circulating blood and 
cerebrospinal fluid that protects the brain from toxins and 
potentially harmful substances (reviewed by Agarwal et 
al. [36]). Although beneficial under normal circumstances, 
the presence of this BBB constitutes a major obstacle 
for drug delivery in the treatment of brain tumors. 
Importantly, quercetin has not only been shown to pass 
the BBB in in vitro systems, but has also been shown to 
accumulate in the brain after oral administration in rats 
[19]. Moreover, quercetin has been shown to function 
as a neuroprotective agent, both in vitro and in vivo 
following ischemia, trauma, or other forms of induced 
brain damage [19, 37–39]. Of particular interest in the 
context of medulloblastoma treatment is the observation 
that administration of quercetin can improve learning and 
memory deficits in animals that were subjected to brain 
damaging agents [40–42].
At low concentrations, quercetin is a potent anti-
oxidant that can scavenge free radicals and bind transition 
metal ions. The neuroprotective effect of quercetin has 
been suggested to be due to this anti-oxidative property. 
However, at higher cellular concentrations (40-100 
μM), quercetin exerts pro-oxidative effects [52–54]. At 
doses above 100 μM alternative mechanisms, such as 
modulation of signal transduction pathways or effects on 
gene expression have also been reported [55]. Quercetin is 
extensively metabolized through glucuronation, sulfation 
and/or methylation. Metabolites were detected in urine, 
plasma and liver homogenate of mice fed with quercetin 
[43]. Formation of different metabolites may explain 
concentration dependent effectiveness, as O-methylated 
metabolites are less protective against peroxide-induced 
damage than quercetin [44] whereas glucurono-sulfo 
metabolites are four times more potent in inhibition 
of LDL oxidation [45]. The relative contribution of the 
different metabolites to the radiosensitization of the 
medulloblastoma cells is currently not known. To test 
which are the major metabolites which would reach 
the tumor in vivo, bioavailability in the brain could be 
studied in preclinical experiments by the use of cerebral 
microdialysis [46] or tissue collection at several endpoints. 
To measure the effects in humans, a phase 0 study could 
be designed to test the concentration of quercetin and its 
metabolites by microdialysis [47], biopsies or surgically 
removed tumor tissues. Quercetin can modulate the 
activity of many kinases and other enzymes (reviewed 
by Russo et al. [48]), which may explain the diversity of 
its actions. Besides neuroprotective properties, quercetin 
has been described to prevent cardiovascular diseases 
Figure 4: Effect of quercetin treatment in combination with irradiation on survival in a xenograft mouse model. 
A. Kaplan-Meier survival analysis of medulloblastoma-bearing mice treated with quercetin (blue line), vehicle (5% DMSO – black line), 
vehicle and irradiation (green line), and quercetin in combination with irradiation (red line). A significant survival extension of the group 
that received ionizing radiation in combination with quercetin as compared to the vehicle-treated group (p=0.0052), the quercetin group 
(p<0.0001), or the group that only received radiotherapy (p=0.002) was observed. B. Graphical representation of survival in days; medians 
are indicated as horizontal lines.
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[49], to function as a chemopreventive agent [50], to 
have anti-proliferative and growth-suppressing effects 
[51], to induce senescence and autophagy [52, 53], and 
to have anti-inflammatory and anti-angiogenic activities 
[54, 55]. Each property or action appears to depend on the 
dose and model system used. Of note are the inhibition 
of the Wnt/β-catenin pathway, which plays an important 
role in one of the four medulloblastoma subgroups [23], 
and the inhibition of the Hepatocyte Growth Factor 
(HGF)-induced cell migration in medulloblastoma by 
quercetin [56]. Furthermore, quercetin has been reported 
to promotes cell apoptosis and in human glioma cell lines 
by the suppression of PI-3-kinase-Akt and ERK signalling 
pathways [57, 58] and induce radiosensitization in tumor 
cells other than medulloblastoma by targeting the ATM-
mediated pathway, which is critical in the DNA damage 
response [59]. Which pathway or mechanism is involved 
in the radiosensitization of medulloblastoma cells by 
quercetin is not exactly known at the moment.
Four distinct molecular subtypes of medulloblastoma 
have been identified [23]. Subclassification of the cell 
lines used in this study showed that the SHH-group like 
and group 3 subtypes were represented, indicating. that the 
mechanism underlying the improved radiation response 
caused by quercetin may be subtype-independent. The 
primary cell cultures used in this study belong to the group 
3 and group 4 subtypes. We did not detect a radiosensitizing 
effect of quercetin in these cells, since these cells are highly 
radiosensitive in vitro and there is no window in which 
quercetin can exert its effect. This was also seen in D458-
med cells, which show high sensitivity to radiation. Since 
the established medulloblastoma cell lines used in our 
experiments may be genetically divergent from de novo 
tumors, it It would be of interest to examine the efficacy 
of quercetin in radioresistant primary medulloblastoma 
cell cultures that resemble the original tumor. In addition, 
the response of primary cell cultures in vitro may not 
necessarily represent the response in the cerebellar 
environment. Therefore, we are setting up more primary 
cell lines of the different subtypes and use these to develop 
orthotopic mouse models to study the effect of quercetin as 
a radiosensitizer in medulloblastoma, in an environment that 
is more comparable to that of the original tumor. However, 
the results presented here indicate that quercetin functions 
as a potent radiosensitizer in medulloblastoma cells at easily 
achievable concentrations, providing a promising lead for 
treatment of children with this type of brain tumor.
MATERIALS AND METHODS
Cell culture and lentiviral infections
Mouse C17.2 neural precursor cells [60], 
human primary fibroblasts (American type culture 
collection; ATCC) and D283-Med, D458-Med, DAOY 
medulloblastoma cell lines were cultured at 37°C in a 5% 
CO2 humidified atmosphere in DMEM plus 10% fetal calf 
serum, 100IU/ml penicillin and 100μg/ml streptomycin 
(PAA Laboratories GmbH, Austria). Pools of D283-
med FM/GC or DAOY FM/GC cells were generated by 
infection with lentiviral vectors, expressing the reporter gene 
combinations Firefly luciferase/mCherry (FM) or Gaussia 
luciferase/Cerulean (GC), as described previously [17]. 
Fluorescence microscopy was used to assess the success 
rate of transductions and cell viability. For intracranial 
injections, cells were harvested and suspended in PBS at a 
concentration of 1 × 108 cells/ml. The cells used in this study 
were not authenticated.
Primary cell culture VU371 was derived from 
tumor tissue, surgically removed from a patient diagnosed 
with medulloblastoma at the VU University Medical 
Center. Informed consent was obtained according to 
institutionally approved protocols. ICb-1299MB is a patient 
derived orthotopic xenograft mouse model of group 4 
medulloblastoma [61] and the xenograft cells were kindly 
provided by Dr. Xiao-Nan Li and Dr. Mari Kogiso (Baylor 
College of Medicine, Houston, TX, USA). VU371 and ICb-
1299MB were cultured at 37°C in a 5% CO2 humidified 
atmosphere in NBM (NeuroBasal Medium)(Invitrogen) 
supplemented with neural stem cell supplement (NSCS), 
N2, stable glutamine (PAA), epidermal growth factor (EGF), 
and basic fibroblast growth factor (bFGF)(PeproTech).
Chemicals
The ActiTarg-K960 chemical library, consisting of 
960 putative kinase inhibitory compounds, was obtained 
from TimTec (Newark, Delaware, USA). Ninety-one 
percent of these compounds conform to four Lipinski 
criteria and 97% to three Lipinski criteria, suggesting 
they have desirable pharmacologic properties [62]. 
Quercetin dihydrate (Calbiochem, USA) was dissolved 
in dimethyl sulfoxide (DMSO; Sigma-Aldrich, USA), 
with a final DMSO concentration of 0.1% for in vitro 
experiments or a final DMSO concentration of 5% for 
in vivo experiments.
Chemical library screen
Seven hundred and fifty DAOY cells were plated 
per well in 96-well plates. The next day, cells in each 
well were treated with a different compound from the 
ActiTarg-K960 library at a 1 μM concentration. Treatment 
was performed with drugs in paired 96-well plates, where 
one plate was exposed to 4 Gy in a Gammacell® 220 
Research Irradiator (MDS Nordion, Canada) 30 minutes 
after addition of the compounds, and the other plate was 
a non-irradiated control. Four days later, cell survival 
was evaluated by measuring Gaussia luciferase (Gluc) 
activity [18], or by means of the Acumen eX3 laser 
scanning cytometer (TTP LabTech, UK). Results were 
analyzed using Acumen Explorer software, calculating 
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the percentage survival for each compound tested with 
the assay. Robustness of the assays was determined by 
calculating the Z’ factor as described by Zhang et al. [63], 
where Z’=0.84 for the Gluc assay and Z’=0.56 for the 
Acumen screen.
Survival assays
Responsiveness of D283-med, D458-med (1,000 
cells/well, or 1 × 104 cells/flask), or DAOY (1,500 cells/
well) medulloblastoma cells to quercetin (1 μM) was 
determined in a cell proliferation assay by use of the 
Acumen eX3 laser scanning cytometer as described 
above, and confirmed by cell counts using a Bürker 
hemocytometer. Viability of primary cells, VU371 and 
ICb-1299MB (2,000 cells/well), after treatment with 1 μM 
quercetin and 0.7 Gy irradiation was determined with Cell 
Titer Glo assay (Promega) according to manufacturer’s 
protocol. In addition, a clonogenic assay was performed 
with different doses of irradiation (0-3 Gy). Therefore, 
exponentially growing D283-med and D458-med cells 
were plated in triplicate in 6-well plates at concentrations 
ranging from 200-2,000 cells/well, and grown for 14 days 
in MethoCult®H4001 with 0, 0.5, or 1 μM quercetin. 
Colonies were counted visually and plating efficiency (PE) 
was calculated by dividing the number of colonies counted 
by the number of cells plated. Surviving fractions (SF) 
were then calculated by dividing the PE by the PE of the 
non-irradiated control per drug concentration. Duplicate 
experiments were performed for each cell line. Analysis of 
inhibitory concentrations was performed using SigmaPlot 
11.0 (Systat Software, Inc. San Jose, CA, USA).
qRT-PCR
Quantitative RT-PCR (qRT-PCR) analysis was 
performed to determine expression of the medulloblastoma 
subgroup classifiers WIF1, SFRP1, NPR3, and KCNA 
in medulloblastoma cell lines and a normal cerebellum 
sample. Total RNA was isolated using the TRIzol RNA 
isolation protocol (Invitrogen, Carlsbad, CA, USA) 
and equal amounts of RNA were converted to cDNA 
using the Omniscript kit (Qiagen). Primer sequences 
for WIF1, SFRP1, NPR3, and KCNA transcripts were 
previously described by Zhao et al. [22] and primers 
were manufactured by Biolegio (Nijmegen, The 
Netherlands). Gene expression of the subgroup classifiers 
in medulloblastoma cells was normalized to GAPDH 
expression levels and the Ct values were used to calculate 
the relative fold difference in mRNA levels (ΔΔCt method) 
compared to normal cerebellum.
D283-med orthotopic xenograft mouse model
Female athymic nude-Fox1nu mice (age 8-10 
weeks; Harlan, Horst, The Netherlands) were maintained 
in accordance with the guidelines and regulations set out 
by the VU University committee on research animal care. 
For intracranial injections, mice were anesthetized with 
2.5% isoflurane in oxygen, and a volume of 5 μl (0.5 × 
106 D283-med FM-GC cells) was injected stereotactically 
into the cerebellum at a rate of 2 μl per minute, using a 
Hamilton 10 μl syringe with a 26G needle. Coordinates 
for injection were determined according to the mouse 
brain atlas [64]: 2.0 mm lateral, 2.5 mm ventral of lambda, 
and at a 2.0 mm depth. Before start of the treatment (three 
weeks after injection of the tumor cells) tumor engraftment 
was determined by measuring Firefly luciferase (Fluc) 
activity. Based on this activity, mice were randomized into 
four treatment protocols: vehicle (5% DMSO), quercetin, 
DMSO/irradiation (4 Gy), and quercetin/irradiation 
(4 Gy). Mice without tumor engraftment (Fluc activity 
<80,000 photons/sec at three weeks after implantation) 
were excluded from the experiment. Quercetin (100 
mg/kg) was administered intraperitoneally at six time 
points: 30 and 60 minutes before-, or after irradiation, 0 
hours, and 24 hours after irradiation. Mice not receiving 
quercetin were treated with the same volume of DMSO 
dissolved in PBS, at the same time intervals as the 
quercetin treated mice. To enable precise positioning of 
the radiation beam on the head and neck area of the mice, 
the animals were anesthetized with ketamin/xylazin. Mice 
that were not irradiated were anesthetized just before the 
zero hours’ time point. Tumor growth was monitored 
semi-weekly by bioluminescent imaging (BLI). In 
short, 150 μl D-luciferin (0.03 g/L, Gold Biotechnoloby, 
St. Louis, USA) was injected intraperitoneally and 10 
minutes after administration mice were anesthetized with 
isoflurane inhalation anaesthesia, positioned in the IVIS 
camera and the bioluminescence signal was determined 
with the IVIS Lumina CCD camera. In addition, the mice 
were monitored daily for discomfort and weight loss. 
When moderate to severe symptoms were present (weight 
loss of >20% or severe neurological deficits), animals 
were sacrificed and brains were removed and formalin-
fixed.
Statistical analysis
A coefficient of variation (CV) and Z’ factor were 
calculated to assess the reproducibility and robustness 
of the small molecule screens, as described by Zhang et 
al. [63], where CV=SD/μ and Z’ = 1-(3σc++3σc-)/Iμc+-μc-I. 
Statistical significance of treatment was assessed using the 
Mann-Whitney U test. Kaplan-Meier survival curves were 
generated with GraphPad Prism 5. Median survival of the 
groups was calculated and survival curves were compared 
with the Log-rank (Mantel-Cox) test. The p values <0.05 
were considered statistically significant.
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